Kaken Pharmaceutical
Clinical trials sponsored by Kaken Pharmaceutical, explained in plain language.
-
New drug KP-001 put to the heart test in healthy volunteers
Knowledge-focused CompletedThis study checks whether KP-001, an experimental drug, affects the heart's electrical activity (QT interval) in 40 healthy adults. Participants receive single doses of KP-001, a placebo, or moxifloxacin (a control) in random order. The goal is to ensure KP-001 does not cause dan…
Phase: PHASE1 • Sponsor: Kaken Pharmaceutical • Aim: Knowledge-focused
Last updated May 17, 2026 08:47 UTC
-
New Drug's dance with statins and coffee revealed in human trial
Knowledge-focused CompletedThis study looked at how a new drug called KP-001 affects the way the body processes rosuvastatin (a cholesterol drug) and caffeine. It also tested how another drug, fluvoxamine, affects KP-001 levels. The trial involved 38 healthy adults and was designed to gather safety and int…
Phase: PHASE1 • Sponsor: Kaken Pharmaceutical • Aim: Knowledge-focused
Last updated May 15, 2026 11:55 UTC
-
Liver function may change how drug KP-001 works in body
Knowledge-focused CompletedThis study looked at how the liver's health affects the way a drug called KP-001 moves through the body and its safety. It included 24 adults, some with liver problems and some healthy. Participants received a single dose of KP-001, and researchers measured drug levels in the blo…
Phase: PHASE1 • Sponsor: Kaken Pharmaceutical • Aim: Knowledge-focused
Last updated May 08, 2026 12:03 UTC